Inventor · disambiguated record
Jeffrey S. Bartlett
Also filed as: BARTLETT JEFFREY · BARTLETT JEFFREY S
10 granted patents·15 pending applications·207 citations·filing 2002–2025
87Inventor score
Files withCSL BEHRING GENE THERAPY INC8CALIMMUNE INC5RAMPART BIOSCIENCE INC5CSL BEHRING LLC2NATIONWIDE CHILDRENS HOSPITAL2
Top patents by PatentIndex Score
25 records- 0195US6962815B2AAV2 vectors and methodsCHILDRENS HOSPITAL INC·Filed 2002·Granted Nov 8, 2005·133 cites·25 claims
- 0292US7749492B2AAV vectors and methodsNATIONWIDE CHILDRENS HOSPITAL·Filed 2005·Granted Jul 6, 2010·67 cites·19 claims
- 0384US10138495B2Bio-production of lentiviral vectorsCALIMMUNE INC·Filed 2017·Granted Nov 27, 2018·3 cites·12 claims
- 0482US10961537B2Compositions and methods for treating beta-hemoglobinopathiesCSL BEHRING GENE THERAPY INC·Filed 2018·Granted Mar 30, 2021·2 cites·27 claims
- 0579US11299752B2Bio-production of lentiviral vectorsCSL BEHRING GENE THERAPY INC·Filed 2018·Granted Apr 12, 2022·1 cites·2 claims
- 0676US2024043845A1Compositions and methods for treating beta-hemoglobinopathiesCSL BEHRING GENE THERAPY INC·Filed 2023·Application pending·0 cites
- 0771US12473568B2Non-immunogenic circular, non-viral DNA vectorsRAMPART BIOSCIENCE INC·Filed 2025·Granted Nov 18, 2025·0 cites·27 claims
- 0870US12473567B2Non-immunogenic circular, non-viral DNA vectorsRAMPART BIOSCIENCE INC·Filed 2025·Granted Nov 18, 2025·0 cites·27 claims
- 0969US11795461B2Compositions and methods for treating beta-hemoglobinopathiesCSL BEHRING GENE THERAPY INC·Filed 2021·Granted Oct 24, 2023·0 cites·21 claims
- 1069US10426798B2Modulatable switch for selection of donor modified cellsCALIMMUNE INC·Filed 2018·Granted Oct 1, 2019·1 cites·17 claims
- 1169US2022315950A1Bio-production of lentiviral vectorsCSL BEHRING GENE THERAPY INC·Filed 2022·Application pending·0 cites
- 1268US11213548B2Modulatable switch for selection of donor modified cellsCSL BEHRING GENE THERAPY INC·Filed 2019·Granted Jan 4, 2022·0 cites·25 claims
- 1366US2025146016A1Non-immunogenic circular, non-viral dna vectorsRAMPART BIOSCIENCE INC·Filed 2025·Application pending·0 cites
- 1466US2025146015A1Non-immunogenic circular, non-viral dna vectorsRAMPART BIOSCIENCE INC·Filed 2025·Application pending·0 cites
- 1566US2022175887A1Methods and compositions for treating conditions using recombinant self-complementary adeno-associated virusUNIV FLORIDA·Filed 2021·Application pending·0 cites
- 1664US2022072046A1Modulatable switch for selection of donor modified cellsCSL BEHRING GENE THERAPY INC·Filed 2021·Application pending·0 cites
- 1759US2024150737A1Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructsRAMPART BIOSCIENCE INC·Filed 2023·Application pending·0 cites
- 1853US2021322331A1Nanocapsules for the delivery of cell modulating agentsCSL BEHRING LLC·Filed 2021·Application pending·0 cites
- 1952US2021238632A1Vector production in serum free mediaCSL BEHRING GENE THERAPY INC·Filed 2021·Application pending·0 cites
- 2047US2021340563A1Donor t-cells with kill switchCSL BEHRING LLC·Filed 2021·Application pending·0 cites
- 2146US2020318080A1Methods and compositions for treating equine conditions using recombinant self-complementary adeno-associated virusUNIV COLORADO STATE RES FOUND·Filed 2017·Application pending·0 cites
- 2244US2019269687A1In Vivo Chemoselection with Low Dose ThioguanineCALIMMUNE INC·Filed 2019·Application pending·0 cites
- 2342US2010260800A1AVV Vectors and MethodsNATIONWIDE CHILDRENS HOSPITAL·Filed 2010·Application pending·0 cites
- 2440US2018140606A1In Vivo Chemoselection with Low Dose ThioguanineCALIMMUNE INC·Filed 2017·Application pending·0 cites
- 2540US2021283222A1Methods and compositions for treating canine conditions using recombinant self-complementary adeno-associated virusCALIMMUNE INC·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jeffrey S. Bartlett files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →